BioCryst Pharmaceuticals (NASDAQ:BCRX) Issues Quarterly Earnings Results, Beats Expectations By $0.15 EPS

BioCryst Pharmaceuticals (NASDAQ:BCRX) announced its earnings results on Wednesday. The biotechnology company reported $0.30 earnings per share for the quarter, topping analysts’ consensus estimates of $0.15 by $0.15, FiscalAI reports. The business had revenue of $218.25 million for the quarter, compared to analyst estimates of $183.28 million. BioCryst Pharmaceuticals had a negative return on equity of 76.36% and a negative net margin of 51.71%.The company’s quarterly revenue was up 33.6% compared to the same quarter last year. During the same period in the prior year, the company earned $0.15 EPS.

Here are the key takeaways from BioCryst Pharmaceuticals’ conference call:

• ORLADEYO revenue rose 10% year over year to $158.2 million on a comparable basis, with continued new-prescriber additions, stable demand and an improved paid rate of 84%.
• The pediatric ORLADEYO pellets launch has begun strongly, with 47 prescriptions received by July 31—above the company’s full-year expectation—and early payer approvals and physician interest described as encouraging.
• BioCryst completed enrollment in the pivotal ALPHA-ORBIT trial of long-acting injectable navenibart ahead of schedule; top-line data are expected in the third quarter of 2027.
• The company raised 2026 total revenue guidance to $690 million-$715 million and lowered non-GAAP operating-cost guidance to $420 million-$440 million, supported by $113.2 million in second-quarter operating profit and more than $350 million in cash and investments.
• BioCryst is shutting down its Birmingham research unit and discontinuing internal discovery programs, shifting to externally sourced assets; management expects lower costs but must establish a stronger pipeline through future business-development transactions.

BioCryst Pharmaceuticals Trading Down 0.4%

BCRX stock traded down $0.03 during midday trading on Wednesday, hitting $8.99. The company had a trading volume of 4,015,576 shares, compared to its average volume of 4,994,886. BioCryst Pharmaceuticals has a 52 week low of $6.00 and a 52 week high of $11.22. The stock’s 50 day moving average price is $9.32 and its 200 day moving average price is $8.67. The stock has a market cap of $2.28 billion, a price-to-earnings ratio of -5.05 and a beta of 0.55.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on BCRX. Weiss Ratings reaffirmed a “hold (c)” rating on shares of BioCryst Pharmaceuticals in a research note on Monday, June 1st. JPMorgan Chase & Co. started coverage on shares of BioCryst Pharmaceuticals in a research report on Monday, July 13th. They set a “neutral” rating and a $12.00 price objective on the stock. Wedbush cut their target price on shares of BioCryst Pharmaceuticals from $22.00 to $21.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. Needham & Company LLC lowered their price target on BioCryst Pharmaceuticals from $18.00 to $16.00 and set a “buy” rating on the stock in a research report on Wednesday, May 6th. Finally, Citizens Jmp lifted their price target on BioCryst Pharmaceuticals from $25.00 to $28.00 and gave the stock a “market outperform” rating in a research note on Thursday, May 7th. Eight analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, BioCryst Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $20.80.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of the company. Invesco Ltd. grew its stake in shares of BioCryst Pharmaceuticals by 40.8% in the fourth quarter. Invesco Ltd. now owns 1,354,897 shares of the biotechnology company’s stock worth $10,568,000 after purchasing an additional 392,521 shares during the last quarter. Mackenzie Financial Corp raised its holdings in shares of BioCryst Pharmaceuticals by 16.6% during the fourth quarter. Mackenzie Financial Corp now owns 150,728 shares of the biotechnology company’s stock valued at $1,152,000 after acquiring an additional 21,411 shares in the last quarter. NewEdge Advisors LLC bought a new stake in BioCryst Pharmaceuticals in the fourth quarter valued at $390,000. XTX Topco Ltd purchased a new stake in shares of BioCryst Pharmaceuticals in the 4th quarter worth about $133,000. Finally, Vestal Point Capital LP purchased a new stake in shares of BioCryst Pharmaceuticals in the 4th quarter worth about $17,550,000. 85.88% of the stock is owned by institutional investors.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.